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Background: Although the radial artery bypass conduit has excellent intermediate-
term patency, it has a proclivity to vasospasm. We tested the hypothesis that brief
pretreatment of a radial artery graft with the irreversible adrenergic antagonist
phenoxybenzamine attenuates the vasoconstrictor response to the vasopressors
phenylephrine and norepinephrine compared with the currently used papaverine/
lidocaine.
Methods: Segments of human radial artery grafts were obtained after a 30-minute
intraoperative pretreatment with a solution containing 20 mL of heparinized blood,
0.4 mL of papaverine (30 mg/mL), and 1.6 mL of lidocaine (1%). The segments
were transported to the laboratory and placed into a bath containing Krebs-Henseleit
solution and 10, 100, or 1000 mol/L phenoxybenzamine or vehicle. The segments
were tested in organ chambers for contractile responses to increasing concentrations
of phenylephrine and norepinephrine (0.5-15 mol/L).
Results: Contractile responses to 15 mol/L phenylephrine in control radial artery
segments averaged 44.2%  9.1% of the maximal contractile response to 30
mmol/L KCl. Papaverine/lidocaine modestly attenuated contraction to 15 mol/L
phenylephrine (32.1%  5.9%; P  .22), but 1000 mol/L phenoxybenzamine
completely abolished radial artery contraction (7.2%  4.4%; P  .001). The
effect of 10 and 100 mol/L phenoxybenzamine on attenuating vasocontraction was
intermediate between 1000 mol/L phenoxybenzamine and papaverine/lidocaine.
Responses to 15 mol/L norepinephrine in control radial artery segments averaged
54.7%  7.5% of maximal contraction to 30 mmol/L KCl. Papaverine/lidocaine
modestly attenuated the contraction response of radial artery segments (35.6% 
5.1%; P  .04). In contrast, 1000 mol/L phenoxybenzamine showed the greatest
attenuation of norepinephrine-induced contraction (10.5%  2.0%; P  .001).
Conclusions: A brief pretreatment of the human radial artery bypass conduit with
1000 mol/L phenoxybenzamine completely attenuates the vasoconstrictor re-
sponses to the widely used vasopressors norepinephrine and phenylephrine. Papav-
erine/lidocaine alone did not block vasoconstriction to these -adrenergic agonists.
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Dissatisfied with the pathologic changesnoted in saphenous vein bypass grafts incoronary artery bypass surgery, Carpen-tier and colleagues,1 in 1973, advocatedthe use of the radial artery (RA) as abypass conduit in the aorta-coronary po-
sition. They noted excellent handling qualities and length.
Two years later, enthusiasm for the RA as a bypass conduit
waned because of the reported high frequency of graft
occlusion that was attributed to vasospasm.2 By 1976, the
use of RA grafts was completely abandoned. However,
Acar and colleagues3 revisited the use of the RA after
several patients in Carpentier and associates’ original series
were found to have patent, disease-free RA grafts after 15
years. In a subsequent series of patients, Acar and col-
leagues found 1- and 5-year patency rates to be 92% and
83%, respectively.4 Others have corroborated these excel-
lent short-term and intermediate-term patency rates of the
RA conduit.5-10 Important to the revival of the RA as a
bypass conduit was the “no-touch” technique of harvesting
a pedicled RA; avoiding endothelial damage by refraining
from using intraluminal probes; using vasodilators such as
papaverine, lidocaine, and nitroglycerin in soaking solu-
tions; and administering parenteral calcium channel block-
ers after surgery. However, the use of the RA is not uni-
versally accepted, possibly because of reports of vasospasm
and myocardial hypoperfusion in the immediate postopera-
tive period despite the use of intraoperative papaverine and
postoperative calcium channel blockers.11,12
In 2000, Taggart and colleagues13 reported that phenoxy-
benzamine (PBZ), a noncompetitive and irreversible -ad-
renergic receptor antagonist, blocked the contraction of the
ex vivo human RA in response to epinephrine. Taggart and
associates pretreated the RA with a soaking solution con-
taining 100 mg of PBZ in 50 mL of heparinized blood (5.9
mmol/L PBZ) and tested the RA segments within 1 hour of
treatment. Subsequently, Velez and colleagues14 demon-
strated that in canine RA a much lower concentration of
PBZ (1 mol/L) blocked the contractile response to increas-
ing concentrations of norepinephrine (NE) and phenyleph-
rine (PE) at 2, 24, and 48 hours after treatment. NE and PE
are most often used for hemodynamic support in the post-
operative period and are used during off-pump coronary
bypass operations to treat hypotension caused by cardiac
elevation and manipulation to visualize posterior and lateral
target vessels. In addition, Velez and associates14 demon-
strated that 1 mol/L papaverine, a vasodilator most often
given intraluminally after the RA graft is harvested, did not
attenuate the vasospasm associated with -adrenergic stim-
uli. In this study, we determined the optimal concentration
of PBZ in a buffered solution used to soak and pretreat RA
segments harvested from patients undergoing coronary ar-
tery bypass graft surgery. The RA graft is typically har-
vested with the surrounding musculofascial pedicle, which
may impede exposure of the vessel to agents designed to
attenuate vasoconstriction, such as papaverine/lidocaine and
PBZ. Therefore, we also tested the hypothesis that perform-
ing an incision through the musculofascial tissue (fas-
ciotomy) would allow greater exposure of the graft to pa-
paverine/lidocaine and PBZ and thereby increase the
efficacy of these agents.
Materials and Methods
Surgical Preparation
RA segments were obtained from unused portions of RA conduits
of patients having elective coronary artery bypass grafting with or
without cardiopulmonary bypass at the Crawford Long Hospital of
Emory University. A modified Allen’s test was performed to
assess the adequacy of preoperative collateral circulation to the
hand.15 The RA was harvested with its pedicle containing the
venae comitantes, perivascular fat, and areolar tissue (no fas-
ciotomy) by using a no-touch technique. Branches of the RA were
ligated with vascular clips. A subset of the RA grafts had the
musculofascial tissue incised (with fasciotomy) to expose the
areolar tissue adjacent to the graft. The RA was then placed in a
solution containing 20 mL of heparinized blood, 1.6 mL of 1%
lidocaine, and 0.4 mL of papaverine (30 mg/mL) for approxi-
mately 30 minutes at room temperature. The RA graft was flushed
intraluminally with the blood/papaverine/lidocaine solution at the
beginning and at 15 minutes of the soaking period to ensure
exposure of the intimal PBZ. Before its placement in the aorto-
coronary position, a small segment of the RA was obtained and
immediately placed in Krebs-Henseleit (K-H) buffer (118 mmol/L
NaCl, 4.7 mmol/L KCl, 1.2 mmol/L KH2PO4, 1.2 mmol/L
MgSO4, 2.5 mmol/L CaCl2, 12.5 mmol/L NaHCO3, and 10
mmol/L glucose) at 4°C, pH 7.4 and transported to our Cardio-
thoracic Research Laboratory.
Experimental Protocol
The RA segment with or without fasciotomy was placed into K-H
buffer (pH 7.4) at 25°C with 10, 100, or 1000 mol/L PBZ or
vehicle. The RA was flushed intraluminally twice with this solu-
tion, once at the beginning and once at the end of a 30-minute
incubation period, which approximates the time between RA har-
vest and placement in the aorta-coronary position. In addition,
control RA segments were obtained before intraoperative pretreat-
ment of the conduit with the papaverine/lidocaine solution and
received no other treatment. The segments were prepared for
placement in organ bath chambers by carefully skeletonizing them
in cold K-H buffer and cutting them into rings 3 to 5 mm in length.
The rings were then mounted on stainless-steel hooks, connected
to FT-03 force displacement transducers, and placed into Radnoti
organ chambers (Radnoti Glass, Monrovia, Calif) containing 7 mL
of oxygenated (95% oxygen/5% carbon dioxide) K-H buffer at
37°C and pH 7.4. Indomethacin (10 mol/L) was added to the
buffer to block responses to endogenous prostanoids. The rings
were stabilized for 1 hour with frequent buffer changes and set to
a predetermined tension that allowed 75% of maximal contraction
to 30 mmol/L KCl.
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The rings were then incubated with increasing concentrations
of PE (0.5-15 mol/L) or NE (0.5-15 mol/L). After the highest
concentration of -adrenergic agent was achieved, 30 mmol/L KCl
was added to the bath to quantify the maximal non–receptor-
mediated constriction. In randomly selected vessels, the integrity
of the RA endothelium was also tested for its receptor-dependent
relaxation response to incremental concentrations of acetylcholine
(ACh), a stimulator of nitric oxide synthase. The rings were
precontracted with the thromboxane A2 mimetic U46619 (1.4
nmol/L) and then exposed to increasing concentrations of ACh (1
nmol/L to 11.7 mol/L) in the presence of 10 mol/L indometh-
acin.
The changes in isometric force were quantified by using an
analog-to-digital converter sampling at 2 Hz. The responses
were analyzed with a Windows-based videographics program
(SPECTRUM; Wake Forest University, Winston-Salem, NC). The
force of contraction elicited by exposure to increasing concentra-
tions of PE and NE was expressed as a percentage of the maximal
contraction generated by KCl in each ring. The degree of relax-
ation after exposure to ACh was expressed as the percentage
tension reduction from the maximal force of contraction obtained
from U46619.
Chemicals
The following drugs were purchased from the Sigma Chemical
Company (St Louis, Mo): acetylcholine chloride, KCl, NE, L-
phenylephrine hydrochloride, K-H buffer, calcium chloride, and
sodium bicarbonate. PBZ hydrochloride (Dibenzyline) was a gift
from SmithKline Beecham Pharmaceuticals (Collegeville, Pa).
Statistical Analysis
Data were analyzed for significance by using a 1-way analysis of
variance comparing the control, papaverine/lidocaine, and PBZ
groups at each concentration of NE and PE. If a significant
difference between groups was assigned by analysis of variance, a
post hoc Student-Newman-Keuls test was applied to locate the
source of differences. All data are reported as mean  SEM.
Results
PE caused a concentration-dependent vasoconstriction in
control RA (n  10) segments; the contraction achieved at
the maximal concentration of PE (15 mol/L) averaged
44.2% 9.1% of the KCl response (Figure 1). Pretreatment
of the RA in papaverine/lidocaine solution (n  32) did not
significantly attenuate the concentration-dependent contrac-
tion responses to PE. Contraction at the highest concentra-
tion of PE was reduced by only 27% of control vessels
(32.1%  5.9%; P  .22). In contrast, PBZ in addition to
papaverine/lidocaine attenuated the vasoconstriction to PE
in a dose-dependent manner (Figure 1). At the highest
concentration of PE used (15 mol/L), the vasoconstriction
response was attenuated by 63% of control at 10 mol/L
PBZ (n  23; 16.5%  4.3%; P  .02), by 80% of control
at 100 mol/L PBZ (n  28; 8.7%  5.1%; P  .003), and
by 116% of control at 1000 mol/L PBZ (n  22; 7.2%
 4.4%; P  .001).
Incremental concentrations of NE also caused progres-
sive vasoconstriction in control human RA segments (n 
11; 54.7%  7.5% of maximal contraction to 30 mmol/L
KCl; Figure 2). Soaking the RA in a combination of papav-
erine/lidocaine blood solution modestly but significantly
attenuated this vasoconstriction response to 15 mol/L NE
(n  36; 35.6%  5.1%; P  .04). Although PBZ at 10
mol/L (n  26) inhibited constriction to concentrations of
NE greater than 7 mol/L, PBZ at 1000 mol/L (n  27)
completely inhibited constrictor responses across all con-
centrations of NE (Figure 2). In summary, 1000 mol/L
PBZ added to papaverine/lidocaine completely inhibits the
vasoconstriction induced by PE and NE.
The potential for fasciotomy at the time of RA harvest to
facilitate exposure of the vessel to PBZ pretreatment was
investigated. At the highest concentration of PE tested (15
mol/L), there was no significant difference between RA
segments with fasciotomy and without fasciotomy with
either papaverine/lidocaine treatment (n  19 with fas-
ciotomy; n  13 without fasciotomy) or PBZ treatment
(1000 mol/L; n  12 with fasciotomy; n  10 without
fasciotomy; Figure 3). Similarly, there was no benefit to
fasciotomy with either papaverine/lidocaine pretreatment (n
 22 with fasciotomy; n  14 without fasciotomy) or PBZ
pretreatment (n  17 with fasciotomy; n  10 without
fasciotomy) when vasoconstriction was achieved by NE
(Figure 4).
RA endothelial function was tested by quantifying the
relaxation response to increasing concentrations of ACh, a
Figure 1. Radial artery vasocontraction responses to increasing
concentrations of phenylephrine, with or without pretreatment
with 3 different concentrations of phenoxybenzamine (PBZ). PBZ
attenuates vasocontraction to phenylephrine in a concentration-
dependent manner. PBZ, Phenoxybenzamine pretreatment; Pap/
Lido, papaverine/lidocaine pretreatment; control, no pretreat-
ment. *P < .05, 103 mol/L PBZ versus 104 and 105 mol/L PBZ,
Pap/Lido, and control. #P < .05, 103 mol/L PBZ versus 105 mol/L
PBZ, Pap/Lido, and control.
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receptor-dependent stimulator of nitric oxide synthase. All
RA segments had similar precontraction tensions generated
by treatment with U46619 (PBZ-treated with fasciotomy,
14.4  1.9 g of tension; PBZ-treated without fasciotomy,
15.0  1.8 g; papaverine/lidocaine with fasciotomy, 13.1
1.4 g; papaverine/lidocaine without fasciotomy, 14.9 
1.6 g; P  .79). Endothelial function was not significantly
attenuated in RA segments in which a fasciotomy was
performed (Figure 5). In the segments treated with papav-
erine/lidocaine, those without fasciotomy (n  10) demon-
strated an 84.6%  6.8% relaxation response to 12 mol/L
ACh, and those with fasciotomy (n  17) demonstrated an
80.7%  5.7% relaxation response (P  not significant). In
the segments treated with 1000 mol/L PBZ in addition to
intraoperative papaverine/lidocaine, those without fas-
ciotomy (n  9) demonstrated an 81.0%  11.8% relax-
ation response to 12 mol/L ACh, suggesting no additional
impairment of endothelial function compared with RA seg-
ments treated with papaverine/lidocaine alone. Those that
had fasciotomy and were treated with PBZ/papaverine/lido-
caine (n  8) showed a trend toward reduced endothelial
function, averaging a 67.6% plusmn; 5.2% relaxation re-
sponse to ACh (P  .33 compared with segments treated
with PBZ/papaverine/lidocaine without fasciotomy; un-
paired Student t test).
Discussion
This study showed that PBZ significantly attenuates the
human RA constriction response to the clinically used va-
sopressors NE and PE in a dose-dependent manner. At a
concentration of 1000 mol/L, PBZ completely blocks va-
socontraction to concentrations of -adrenergic agents that
are typically used during off-pump surgery to treat intraop-
erative hypotension and that are used after surgery to sustain
systemic blood pressure. PBZ at concentrations of 100 and
10 mol/L has some efficacy in attenuating RA vasocon-
traction; however, these concentrations do not completely
Figure 2. Radial artery vasocontraction responses to increasing
concentrations of norepinephrine, with or without pretreatment
with 3 different concentrations of phenoxybenzamine (PBZ). PBZ
attenuates vasocontraction to norepinephrine in a concentration-
dependent manner. PBZ, Phenoxybenzamine pretreatment; Pap/
Lido, papaverine/lidocaine pretreatment; control, no pretreat-
ment. *P < .05, 103 mol/L PBZ versus 104 and 105 mol/L PBZ,
Pap/Lido, and control. #P < .05, 103 mol/L PBZ versus 105 mol/L
PBZ, Pap/Lido, and control.
Figure 3. Radial artery vasocontraction responses to 15 mol/L
phenylephrine, with and without fasciotomy after treatment with
103 mol/L phenoxybenzamine or papaverine/lidocaine. PBZ,
Phenoxybenzamine pretreatment; Pap/Lido, papaverine/lidocaine
pretreatment. There were no significant differences between
fasciotomy and no fasciotomy in the efficacy of PBZ or papaver-
ine/lidocaine against 15 mol/L phenylephrine.
Figure 4. Radial artery vasocontraction responses to 15 mol/L
norepinephrine, with and without fasciotomy after treatment with
103 mol/L phenoxybenzamine or papaverine/lidocaine. PBZ,
Phenoxybenzamine pretreatment; Pap/Lido, papaverine/lidocaine
pretreatment. There were no significant differences between
fasciotomy and no fasciotomy in the efficacy of PBZ or papaver-
ine/lidocaine against 15 mol/L norepinephrine.
Cardiopulmonary Support and Physiology Corvera et al
1552 The Journal of Thoracic and Cardiovascular Surgery ● November 2003
CSP
block the response to NE and PE compared with 1000
mol/L PBZ, which completely blocked vasoconstriction
but also unmasked the vasodilatation component of the
mixed - and -adrenergic agent NE. Furthermore, per-
forming an incision in the fascial plane to expose the graft
to topical vasodilators does not increase the efficacy of
either PBZ or papaverine/lidocaine. A pedicled harvest of
the RA to avoid graft trauma, combined with pretreatment
of the RA with 1000 mol/L PBZ to block vasospasm from
-adrenergic stimuli, may be important in preventing RA
graft vasospasm and its complications, especially in the
early postoperative period.
The optimal concentration at which PBZ completely
abolished adrenergically induced vasoconstriction was
1000-fold greater than that reported for canine RA by Velez
and colleagues.14 There is likely a species difference in
response to -adrenergic agents between human beings and
dogs that may be related to the density of adrenergic recep-
tors. In addition, the RAs arteries were skeletonized in the
study by Velez and colleagues, and this may facilitate
exposure to PBZ. It was thought that the presence of the soft
tissue pedicle surrounding the human RA graft impedes
contact of PBZ with the graft. However, in this study,
increasing the exposure of the graft via fasciotomy did not
change the efficacy of PBZ or papaverine/lidocaine. Com-
plete skeletonization of the RA graft was not performed, as
advocated by Taggart and colleagues,16 because skeleton-
ization is contrary to the no-touch technique to avoid con-
duit trauma and may encourage vasospasm.
The optimal concentration used in this study is 6-fold
less than that used by Taggart and colleagues.16 Concentra-
tions of PBZ higher than 1000 mol/L are unnecessary
because 1000 mol/L PBZ effectively blocks vasoconstric-
tion by -adrenergic agents. The formulation of PBZ used
by both this study and that of Taggart and colleagues is a
highly acidic solution composed of ethanol, hydrochloric
acid, and propylene glycol that must be properly buffered to
avoid endothelial or other cellular injury. The pH of Taggart
and associates’ blood/PBZ solution was not reported. How-
ever, Taggart and colleagues13 and Dipp and colleagues17
demonstrated full endothelial function with a blood-based
solution of greater than 1000 mol/L PBZ. In this study,
PBZ at a concentration of 1000 mol/L in a buffered
crystalloid solution did not cause endothelial dysfunction.
However, papaverine alone has been shown to cause a
decrease in endothelium-dependent relaxation by ACh in
internal thoracic arteries and RAs.17-20 We observed that the
use of papaverine/lidocaine in RA segments attenuated the
endothelium-dependent relaxation response to ACh by 15%
to 20% (data not shown). The use of papaverine in RA
grafting is deleterious to the endothelium of the conduit;
however, a properly buffered blood- or crystalloid-based
solution of 1000 mol/L PBZ does not cause endothelial
dysfunction.
External exposure alone via simple immersion of the
graft in a PBZ solution may not be optimally effective.
Because the vasa vasorum of the RA does not penetrate the
muscular vessel media,21-23 we also flushed the RA conduit
intraluminally to maximize exposure of the graft to the
agents.
In summary, pretreatment of the RA conduit with PBZ
attenuates the vasoconstrictor response to the widely used
vasopressors NE and PE. The efficacy of 1000 mol/L PBZ
is not enhanced by increasing external exposure of the graft
via an incision in the soft tissue pedicle (fasciotomy); how-
ever, gentle intraluminal flushing is important for delivering
the drug to the muscular vessel media. RA vasospasm is
effectively blocked ex vivo by carefully preserving the soft
tissue pedicle protecting the graft and pretreating the con-
duit with PBZ. Endothelial function is preserved with the
use of PBZ. Therefore, we recommend the no-touch tech-
nique of RA harvesting and brief pretreatment of the RA
graft with 1000 mol/L PBZ.
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